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ABSTRACT
Tumor initiating cells (TICs), responsible for tumor initiation, and cancer stem 
cells (CSCs), responsible for tumor expansion and propagation, are often resistant to 
chemotherapeutic agents. To find therapeutic targets against sarcoma initiating and 
propagating cells we used models of myxoid liposarcoma (MLS) and undifferentiated 
pleomorphic sarcoma (UPS) developed from human mesenchymal stromal/stem cells 
(hMSCs), which constitute the most likely cell-of-origin for sarcoma. We found that 
SP1-mediated transcription was among the most significantly altered signaling. To 
inhibit SP1 activity, we used EC-8042, a mithramycin (MTM) analog (mithralog) with 
enhanced anti-tumor activity and highly improved safety. EC-8042 inhibited the growth 
of TIC cultures, induced cell cycle arrest and apoptosis and upregulated the adipogenic 
factor CEBPα. SP1 knockdown was able to mimic the anti-proliferative effects induced 
by EC-8042. Importantly, EC-8042 was not recognized as a substrate by several ABC 
efflux pumps involved in drug resistance, and, opposite to the chemotherapeutic 
drug doxorubicin, repressed the expression of many genes responsible for the TIC/
CSC phenotype, including SOX2, C-MYC, NOTCH1 and NFκB1. Accordingly, EC-8042, 
but not doxorubicin, efficiently reduced the survival of CSC-enriched tumorsphere 
sarcoma cultures. In vivo, EC-8042 induced a profound inhibition of tumor growth 
associated to a strong reduction of the mitotic index and the induction of adipogenic 
differentiation and senescence. Finally, EC-8042 reduced the ability of tumor cells to 
reinitiate tumor growth. These data suggest that EC-8042 could constitute an effective 
treatment against both TIC and CSC subpopulations in sarcoma.
INTRODUCTION
Sarcomas often show a limited clinical response 
to cytotoxic drugs which still remain as the most utilized 
agents for generalized treatment of soft tissue sarcomas 
[1]. A hypothesis to explain the resistance of sarcomas 
to chemotherapy is the existence of drug-resistant 
CSCs, which are responsible of tumor progression and 
propagation. These subpopulations of CSCs emerge 
during tumor evolution from the cell-of-origin or TICs, 
which are the normal cells that acquire the first cancer-
promoting mutations and initiate tumor formation [2]. 
It has been recently established that transformed MSCs 
and/or their immediate lineage progenitors are the most 
likely cell-of-origin for many types of sarcomas [3, 
4]. Accordingly, many efforts have been undertaken 
to produce models of sarcomas based on MSCs 
transformed with relevant oncogenic events. This kind 
of models constitutes unparalleled systems to unravel the 
mechanisms underlying sarcomagenesis from the cell of 
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origin, to explore the evolution of CSCs subpopulations 
and to search for specific therapies able to eliminate these 
populations.
In the search for new therapeutic targets, 
transcription factors (TFs) presenting altered activity 
offer a promising choice since they are pivotal points in 
signaling pathways and therefore their inhibition may 
block several routes involved in tumor progression [5]. In 
this line, several members of the SP family of TFs, such as 
SP1, SP3 and SP4, have been found to play an important 
role in the pathogenesis of some cancers including 
sarcomas and may constitute relevant therapeutic targets 
[6-10]. MTM is an antitumoral antibiotic natural product 
that binds preferentially to GC-rich sequences in DNA and 
prevents the binding of SP TFs in gene promoters, thus 
inhibiting the transcription of SP-regulated genes [11]. 
MTM showed strong response rates in cancer treatment 
although its clinical use was limited due to its adverse side 
effects [12]. Nevertheless, new studies reporting specific 
modes of action in certain histologies, like Ewing sarcoma 
[13], has renewed the interest in MTM and have warranted 
the development of two clinical trials (http://www.
clinicaltrials.gov, NCT016110570 and NCT01624090).
Genetic engineering of the MTM biosynthesis 
pathway has been used to generate mithralogs showing an 
efficient inhibition of the SP-mediated gene expression and 
bearing both lower toxicity and higher biological activity 
[14-16]. Recently, the new mithralog demycarosyl-3D-
β-D-digitoxosyl-mithramycin SK (EC-8042; DIG-MSK) 
has been obtained and characterized [17]. As expected, 
EC-8042 preferentially binds GC-rich sequences, is a 
potent inhibitor of SP-driven gene expression and shows 
pleiotropic anti-angiogenic and anti-oncogenic activities 
[18-20]. EC-8042 altered the expression of cell cycle 
related genes resulting in cell cycle arrest and apoptosis 
in breast cancer cell lines [21]. In Ewing sarcoma, EC-
8042 was substantially less toxic than mithramycin 
but maintained suppression of EWS-FLI1 at similar 
concentrations as MTM, and markedly suppressed Ewing 
sarcoma xenograft growth [22]. More importantly, EC-
8042 shows a potent in vitro and in vivo antitumor activity 
against several tumors types similar to other analogues 
but is 10-fold less toxic in vivo than MTM [17], enabling 
it as the lead candidate in the quest for mithralogs with 
improved therapeutic window potentially useful in the 
clinical setting.
We have recently established and characterized 
pioneer models of UPS and MLS developed from 
sequentially mutated human bone marrow-derived MSCs 
(hBMSCs) [23-25]. To find specific therapies able to 
target TICs in sarcoma we search for altered TF-mediated 
signaling in these sarcoma models. We found that SP1-
mediated transcription was among the most significantly 
altered signaling and that the inhibition of SP1 expression 
and activity by EC-8042 efficiently inhibited the in vitro 
and in vivo growth in these models of sarcoma initiating 
cells. EC-8042 repressed the expression of important 
genes associated to the TIC/CSC phenotype and was 
able to inhibit the growth of tumorsphere cultures and the 
ability to reinitiate tumor growth, suggesting that EC-8042 
could constitute an effective treatment against both the 
TIC and the CSC subpopulations in sarcoma.
RESULTS
SP1-mediated signaling is altered in sarcoma-
initiating transformed hBMSCs
We have previously developed and characterized 
sarcoma models using hBMSCs sequentially mutated 
with up to 5 oncogenic events. This collection of hBMSCs 
ranges from wt (MSC-0H) to fully transformed hBMSCs 
(MSC-5H). In addition, the fusion oncogene FUS-CHOP 
(FC), characteristic of MLS, or the corresponding GFP-
control, is ectopically expressed in all the MSC types 
(Supplementary Figure S1A) [23-25]. MSC-4H-GFP cells 
are immortalized, but not transformed and the rest of the 
MSC types are transformed and originate sarcomas in vivo 
[23, 25]. Thus, MSC-5H-GFP give rise to pleomorphic 
undifferentiated sarcomas, meanwhile FUS-CHOP-
expressing hBMSCs (MSC-4H-FC, and MSC-5H-FC) 
initiate MLS-like tumors. Several cell lines were also 
derived from xenograft tumors generated by transformed 
hMSCs (T-4H-FC#1, T-4H-FC#3, T5H-GFP#1 and T5H-
FC#1) (Supplementary Figure S1A).
To identify altered signaling in this sarcoma TICs we 
performed a gene-expression profiling (GEP) comparing 
wild type and transformed hBMSCs types. Ingenuity 
Pathway Analysis (IPA) of differentially expressed 
genes revealed the upstream regulation signaling most 
significantly altered in MSC-5H-GFP, MSC-5H-FC and 
T-5H-FC#1 cells (Supplementary Figure S1B). All these 
cell types displayed a similar pattern of transcription 
factor-mediated signaling deregulation, with SP1-
mediated transcription being the most significantly altered 
signaling that showed a higher positive activation z-score 
(a predictive value of activation/inhibition) in all cell 
lines (Supplementary Figure S1B). Accordingly, RT-PCR 
analysis showed that the expression of SP1 and two known 
SP1-target genes, C-MYC and XIAP, was upregulated in 
MSC-5H-GFP, MSC-5H-FC, T-5H-GFP#1 and T-5H-FC#1 
cells (Figure 1A). Importantly, 24 hours-treatment with 0.5 
μM EC-8042 efficiently inhibited the expression of SP1 and 
their downstream targets, both at mRNA and protein level, 
in MSC-5H-FC#1 and T-5H-FC#1 cells (Figure 1B–1C). 
Moreover, EC-8042 also decreased the expression of other 
members of the SP family which may show certain level 
of overlap with SP1-induced signaling [6]. Thus, EC-8042 
treatment inhibited the expression of SP3 in both MSC-5H-
FC#1 and T-5H-FC#1 cell types and SP4 in MSC-5H-FC 
(Supplementary Figure S2). In addition, it was previously 
reported that SP1 repressed the expression of the adipogenic 
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factor C/EBPα [26]. In line with this finding, the inhibition 
of SP1 activity with EC-8042 resulted in a concentration-
dependent activation of C/EBPα (Figure 1D).
Antiproliferative effects of EC-8042
Opposite to wild type hBMSCs, all cell types of 
the 4H- (Figure 1E) and 5H- models (Figure 1F) were 
sensitive to sub-micromolar concentrations of EC-8042 or 
doxorubicin (IC50 between 0.107 and 0.311 μM for EC-
8042 and between 0.086 and 0.604 μM for doxorubicin). 
Likewise, EC-8042 showed a similar cytotoxic effect 
on a low-passaged primary sarcoma patient-derived 
cell line (Supplementary Figure S3A). To explore the 
mechanism underlying the antiproliferative effect of 
EC-8042, we examined the effect of this drug on the cell 
Figure 1: Antiproliferative effects of EC-8042. A. mRNA expression of SP1 and SP1-downstream genes (C-MYC and XIAP) in 
MSC5H-GFP and MSC-5H-FC (left panel) and T-5H-GFP#1 and T-5H-FC#1 cells (right panel) relative to hBMSCs. B. mRNA expression 
of SP1 and SP1-downstream genes (C-MYC and XIAP) in MSC5H-FC (left panel) and T5H-5H-FC#1 cells (right panel) treated with 
0.5μM EC-8042 for 24 hours, relative to untreated (DMSO) controls. C. Protein levels of SP1, C-MYC, XIAP and β-actin in MSC5H-FC 
and T5H-5H-FC#1 cells treated with 0.5μM EC-8042 for 24 hours. D. C/EBPα protein level upregulation after 48h- (MSC-5H-FC) or 
24h-treatment (T-5H-FC#1) with the indicated concentrations of EC-8042. E–F. Cell viability (WST1 assay) measured after the treatment 
of wild-type hBMSCs and the indicated MSC-4H and T-4H (E) or MSC-5H and T-5H cell lines (F) with increasing concentrations of EC-
8042 (left panels) or doxorubicin (middle panels) for 48 hours. IC50 values for each cell type are shown (right panels). G. Time-course 
evolution of the cell cycle distribution of MSC-5H-FC cells treated with increasing concentrations of EC-8042. H. Apoptotic cleavage of 
PARP in MSC-5H-FC and T-5H-FC#1 cells treated with 0.5μM EC-8042 or 0.5μM doxorubicin for the indicated times. The expression 
of β-actin was used as loading control in western blotting analysis. Error bars represents the standard deviation and asterisks indicate a 
statistically significant difference with the respective control groups (*:p<0.05; two-sided Student t test).
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cycle distribution. MSC-5H-FC cells treated with 0.1 μM 
EC-8042 showed a slow transition through the S-phase 
followed by G2 arrest, meanwhile cells treated with a 
higher concentration also showed a relevant increment 
in the Sub-G1 apoptotic population at latter times (Figure 
1G). In line with this result, MSC-5H-FC and T-5H-FC#1 
cells treated with low concentrations (0.01-0.05 μM) 
of EC-8042 stained positive for senescence-associated 
β-galactosidase activity (Supplementary Figure S4), 
suggesting the induction of a senescence-like state, while 
higher concentrations of EC-8042 (0.5 μM) induced a 
time-dependent poly (ADP-ribose) polymerase (PARP) 
apoptotic cleavage in a similar way to doxorubicin (Figure 
1H). Thus, EC-8042 treatment induced cell cycle arrest 
followed by apoptotic cell death in sarcoma TICs.
To confirm that SP1 inhibition mediates the anti-
proliferative effects of EC-8042, we performed siRNA 
knockdown of this transcription factor in MSC-5H-FC 
cells. Two different siRNA duplexes inhibit SP1 protein 
expression to levels comparable to that observed after a 
24 hour treatment with EC-8042. These SP1 knockdowns 
correlate with the inhibition of C-MYC and the induction 
of PARP apoptotic cleavage (Figure 2A). Likewise, SP1 
depletion induces a time-dependent cytotoxic effect 
(Figure 2B). Therefore, SP1 knockdown seems to mimic 
the anti-proliferative effects induced by EC-8042.
EC-8042 decreases the expression of ABC 
transporters and is not a substrate for them
Previous reports showed that the expression of 
several members of the ATP binding cassette (ABC) 
transmembrane protein family is regulated by SP1 and 
can be repressed by MTM treatment [27-29]. These ABC 
proteins act as efflux pumps for drugs and metabolites 
and cause drug resistance in tumor cells. Therefore, we 
studied the effect of EC-8042 on the expression of the 3 
members of the family most commonly involved in drug 
resistance of cancer cells. EC-8042 was able to decrease 
the expression of ABCB1 (MDR1), ABCG2 (BCRP1) 
and ABCC1 (MRP1) in MSC-5H cells (Figure 3A). 
Nevertheless, neither MTM nor EC-8042 inhibited the 
pumping activity of ABC transporters (Figure 3B). More 
importantly, a functional assay showed that ABCG2 and 
ABCB1 proteins failed to transport both MTM and EC-
8042 (Figure 3C). This behavior is in stark contrast to most 
chemotherapeutic agents, including doxorubicin, which 
are known substrates of ABC transporters [30]. Given 
that drug resistance caused by enhanced ABC proteins 
expression and activity is a hallmark of both normal stem 
cells and CSCs [31], the inability of ABC transporters 
to pump out EC-8042, together with the capacity of this 
mithralog to repress the expression of ABC transporters 
genes, suggest that EC-8042 could efficiently target CSC 
subpopulations.
EC-8042 decreases the expression of genes 
associated to the CSC phenotype
To gain further insight about the ability of EC-8042 
to affect the CSC phenotype in sarcoma, we performed RT-
PCR in T-5H-FC#1 cells treated for 24h with 0.5 μM EC-
8042 or doxorubicin to analyze the expression of an array 
of 84 genes with well known functions in pluripotency, 
self-renewal, migration, metastasis and signal transduction 
in CSCs as well as several CSC markers. EC-8042 and 
doxorubicin induced statistical significant changes (fold 
change≥2; p-value<0.05) in the expression of 42 and 
30 genes respectively (Figure 4A–4D). Notably, the 
way these drugs altered CSC-related gene expression is 
strikingly different. Most genes affected by doxorubicin 
treatment were upregulated (21 upregulated genes and 
9 downregulated genes) (Figure 4B & 4D), whereas 
EC-8042-treatment induced the downregulation of 
almost all the altered genes (3 upregulated genes and 39 
downregulated genes) (Figure 4A & 4C). Confirming 
the effect of EC-8042 over SP1-mediated transcription, 
several genes known to be controlled by SP1 were 
Figure 2: SP1 knockdown mimics EC-8042 antiproliferative effects. A. Protein levels of SP1, C-MYC and cleaved-PARP in 
MSC-5H-FC cells 48 hours after the transfection of the indicated siRNAs (lanes 1-3) or after a 24 hours-treatment with 0.5μM EC-8042 
(lane 4). β-Actin levels are presented as a loading control. B. Effect of siRNAs on the cell viability (WST1 assay relative to siControl 
values) of MSC-5H-FC cells measured 48 or 72 hours after transfection. Error bars represents the standard deviation (n=3 independent 
experiments) and asterisks indicate a statistically significant difference with the respective control groups (*:p<0.05, **:p<0.005; two-sided 
Student t test).
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downregulated in EC-8042 treated cells, including 
HDAC1, ITGA2, KIT, ENG, PLAUR or C-MYC. The genes 
repressed by EC-8042 included important pluripotency 
factors like SOX2 and C-MYC, markers of CSCs in 
different types of tumors, including sarcomas, like ENG/
CD105, ABCG2, KIT/CD117, CD44 and ALCAM/CD166, 
genes involved in proliferation and asymmetric division 
such as LIN28B, ERBB2, SIRT1 and KITLG, genes 
involved in metastasis like TWIST1, ZEB1 and PLAT and 
genes involved in relevant stemness signaling pathways 
like NOTCH signaling (NOTCH1, MALML1 and JAG1), 
NFκB signaling (NFκB1 and IκBKB) or Hippo signaling 
(TAZ, WWC1, LATS1 and YAP1) (Figure 4C). On the other 
hand, Doxorubicin upregulated pluripotency genes such as 
NANOG and POU5F1/OCT3/4, CSC markers like THY1/
CD90, ALDH1A1, PROM1/CD133, KIT/CD117, CD24, 
CD38, genes involved in metastasis like TWIST1, TWIST2 
and ZEB2 and genes involved in signaling pathways like 
NOTCH signaling (DLL1, DLL4 and NOTCH2), while 
also induced the downregulation of genes like SOX2, ID1 
or ZEB1 (Figure 4D). IPA analysis of the group of genes 
differentially expressed after the treatments also showed 
that pluripotency signaling pathways were activated by 
doxorubicin but were inhibited by EC-8042 (Figure 4E). 
Figure 3: EC-8042 downregulates the expression of ABC transporters and is not a substrate for them. A. Relative mRNA 
expression of ABCG2, ABCB1 and ABCC1 genes in MSC-5H-GFP and MSC-5H-FC cells treated with the indicated concentrations 
of EC-8042 for 24 hours. B. ABCG2 and ABCB1 functional inhibition assay for EC-8042 and MTM. Cladribine/Ko243 and digoxin/
valspodar were used as negative/positive control drugs for ABCG2 and ABCB1 respectively. C. ABCG2 and ABCB1 functional substrate 
assay for EC-8042 and MTM. Ko243 and valspodar were used as transporter inhibitors for ABCG2 and ABCB1 respectively. Error bars 
represents the standard error of the mean (SEM) and asterisks indicate a statistically significant difference with the respective control groups 
(*:p<0.05; two-sided Student t test).
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Figure 4: Changes in CSC-related gene expression induced by EC-8042 and doxorubicin. RNA derived from T5H-FC#1 
cells treated with the carrier substance (DMSO) or with 0.5 μM EC-8042 or 0.5 μM doxorubicin for 24 hours were used to analyzed 
the expression of 86 CSC-related genes (RT2 Profiler™ PCR Array System PAHS-176Z, Qiagen). A–B. Scatter plots representing the 
expression values in control (DMSO) and EC-8042- (A) or doxorubicin- (B) treated cells for each gene. Genes above and below the dark-
red lines are expressed more than two fold up (red symbols) or down (green symbols) in treated versus untreated cells respectively. C–D. 
List of genes differentially expressed (fold change ≤-2 or ≥2 and p-value (two sided Student t test) < 0.05) after EC-8042 (C) or doxorubicin 
(D) treatment. E. Comparison of genes differentially expressed after EC-8042 and doxorubicin treatment using the IPA software. The 
heat map of the mostly altered signaling pathways sorted by their variation in the activation z-score is presented. F. Expression of SOX2, 
C-MYC, NOTCH1, NFκB1 (p50 and p105) and SIRT1 proteins in T5H-5H-FC#1 cells treated with 0.5μM EC-8042 for 24 hours. The 
expression of β-actin was used as loading control.
Oncotarget30941www.impactjournals.com/oncotarget
Western blotting analysis confirmed the repression of 
SOX2, C-MYC, NOTCH1, NFκB1 (p50 and p105) and 
SIRT1 protein synthesis by EC-8042 (Figure 4F).
These data are in line with previous works reporting 
that CSCs are resistant to doxorubicin treatment and 
therefore this drug may favor a CSC positive selection 
[32], and on the other hand, suggest that EC-8042 
treatment may disadvantage the CSC phenotype in 
sarcomas.
EC-8042 eliminates CSC subpopulations in vitro
To test whether EC-8042 may affect CSC 
subpopulations, we assayed the ability of the drugs to 
inhibit the formation of clonal spheres (tumorspheres) 
in nonadherent and serum free culture conditions 
(Figure 5A) [33]. EC-8042 efficiently reduced the 
number (Figure 5B–5C) and viability (Figure 5D) of 
the tumorespheres formed from MSC-5H-FC and T-5H-
FC#1 cells in a dose-dependent manner. Likewise, EC-
8042 treatment efficiently prevent tumorsphere formation 
from a primary patient-derived cell line (Supplementary 
Figure S3B). To further confirm the effect of EC-8042 
on CSC subpopulations, we assayed cell viability after 
direct treatment of tumorsphere cultures (Figure 6A). 
After treatment with doxorubicin and especially with 
EC-8042, tumorspheres were smaller and displayed a 
disrupted and irregular morphology in all cell types (4H 
and 5H models) (Figure 6B & Supplementary Figure 
S5A-5B). Both drugs were able to induce apoptosis in 
tumorsphere cells as shown by PARP apoptotic cleavage 
induction both in situ (Figure 6C) or at protein level 
(Figure 6D). In any case, EC-8042 was much more 
efficient than doxorubicin in reducing the cell viability 
of tumorsphere cultures in all the studied sarcoma TICs 
(Figure 6E-6H). These results support that, in contrast 
Figure 5: Effect of EC-8042 on tumorsphere-formation capacity. A. Adherent cultures of sarcoma TICs were treated for 3 days 
with DMSO (carrier substance) or EC-8042. After wards that cells were plated at low density in tumorsphere medium and let to form 
tumorspheres for 10 days. Tumorspheres formed were scored, recovered, disaggregated and assayed for cell viability. B. Representative 
images of tumorspheres formed from MSC-5H-FC and T-5H-FC#1 cells treated with the indicated concentrations of EC-8042. Scale bars= 
100μm. C–D. The effect of the drugs was estimated by scoring the number of tumorspheres formed relative to the untreated condition (C) 
or by measuring their cell viability (WST1 assay) (D) (n=3 independent experiments). Error bars represents the standard deviation.
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Figure 6: Effect of EC-8042 and doxorubicin on tumorsphere cultures. A. Sarcoma TICs were plated at low density in CSC 
medium and let to form tumorspheres for 10 days followed by a 4-day treatment with DMSO (carrier substance), EC-8042 or doxorubicin. 
After treatment, the remaining tumorspheres were recovered, disaggregated and assayed for cell viability. B. Representative images of MSC-
5H-GFP and MSC-5H-FC sarcosphere cultures treated with DMSO, 1 μM EC-8042 or 1 μM doxorubicin for 4 days. Scale bars= 200μm. 
C. Detection of cleaved PARP in GFP-positive T5H-FC#1 tumorspheres treated with DMSO, 0.5μM EC-8042 or 0.5μM doxorubicin for 
48h. D. Western blot analysis showing the apoptotic cleavage of PARP in MSC-5H-FC and T-5H-FC#1 tumorsphere cultures treated with 
DMSO, 0.5μM EC-8042 or 0.5μM doxorubicin for the indicated times. E–H. Cell viability (WST1 assay) measured after the treatment of 
MSC-4H (E), T-4H (F), MSC-5H (G) and T-5H (H) tumorsphere cultures with the indicated concentrations of EC-8042 or doxorubicin. 
Error bars represents standard deviation.
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to doxorubicin, EC-8042 could constitute an effective 
treatment to eliminate CSC subpopulations in sarcoma.
EC-8042 inhibits the growth of MLS xenografts 
through the induction of a senescent-like state
EC-8042 treatment induced a profound tumor 
growth inhibition in MLS xenografts originated from 
T-5H-FC#1 cells (Figure 7 & Supplementary Figure S6). 
A reduction in tumor growth was observed early during 
the treatment and highly significant differences in tumor 
volume and luminiscence levels between control and EC-
8042-treated tumors were observed as soon as 5-8 days 
after the beginning of the treatment (Figure 7A–7B). At 
the end-point, two different experiments displayed TGI 
percentages of 61.4 and 76.42% respectively, and showed 
highly significant differences in survival (Figure 7A 
& 7C and Supplementary Figure S6). Likewise, tumor 
weights in the control series almost triplicated those of 
the EC-8042-treated series at the end of the experiment 
(Figure 7D). On the other hand, doxorubicin treatment 
showed lower antitumor activity compared to EC-8042 
and resulted toxic at the later time points (Figure 7E). To 
examine the ability of drugs to target CSC subpopulations 
in vivo, we harvested xenograft tumors after a single high 
dose (50 mg/Kg) treatment of EC-8042 or doxorubicin and 
dissociated them into single cells to evaluate their self-
renewal and tumor re-initiation ability. A non-significant 
reduction in tumorshpere formation was observed in 
EC-8042-treated tumors (Figure 7F). More importantly, 
EC-8042 produced a delay in tumor formation after re-
implantation of tumor cells in limiting dilution assays. We 
initially (week 3) observed a 4-fold significant decrease 
of TIF in EC-8042- versus control-treated tumors (Figure 
7G). Although eventually (week 5) tumor growth was 
detected in nearly all mice (13 out of 15 in control and 
EC-8042 groups and 12 out of 12 in doxorubicin group), 
tumor weights in the EC-8042 group were significantly 
lower than in control group (Figure 7H). These data 
suggest that EC-8042 is able to partially reduce CSCs 
subpopulations in vivo.
Intra-tumor pharmacokinetic measurement of EC-
8042 concentration at 24h and 48h after 50 mg/kg single 
dose treatment indicated that the drug accumulated at 
doses higher that those deemed active in vitro: 1640 ± 105 
ng/g (media ± standard deviation) at 24h and 412 ± 267 
ng/g at 48h. This high dose treatment of EC-8042 is below 
the single maximum tolerated dose [17] and was able 
to produce tumor regression in a lung cancer xenograft 
model (unpublished data).
Histological examination of tumors showed that, 
in comparison with control tumors, EC-8042-treated 
tumors presented more extended areas of myxoid pattern 
and increased adipogenic differentiation (Figure 8A). In 
addition, both doxorubicin and especially EC-8042 treated 
tumors presented significantly lower mitotic counts than 
untreated tumor samples (Figure 8A–8B). Moreover, all of 
the tumors of the control and doxorubicin series displayed 
a necrotic central area associated to their aggressive 
growth pattern, and the appearance of this necrotic area 
is largely prevented by EC-8042 treatment (Figure 8A 
& 8C). Therefore, tumors treated with EC-8042 showed 
a significant reduction in tumor grade according to the 
score obtained by applying the three-grade FNCLCC 
system which depend on the necrosis, mitotic counts 
and differentiation status of the tumors (Figure 8D). 
Immunohistochemical analysis confirmed a decrease of 
C-MYC nuclear and cytosolic expression in EC-8042 
treated tumors which did not reach statistical significance 
(Figure 8A & 8E). Likewise, in line with the observed 
increase in adipogenic differentiation, EC-8042 produced 
an increase in the expression of C/EBPα (Figure 8A & 
8F), which is in any case much more modest than that 
observed in TICs cultures. In addition, only doxorubicin 
treatment induced a significant increment in apoptotic cell 
death (cleaved-PARP staining) (Figure 8A & 8G). The fact 
that EC-8042-treated tumors showed a great reduction 
in the mitotic index suggest that this drug could induce 
a senescent-like state associated to a permanent cell-
cycle arrest, as previously observed for other anti-tumor 
drugs [34, 35]. To test this possibility, we disaggregated 
and placed-back in culture four different tumors from 
each group and we analyze senescence-associated 
β-galactosidase in these ex vivo-established cell lines. 
Cultures derived from EC-8042-treated tumors showed 
a pronounced increase in size characteristic of senescent 
cells and a large and significant increase in the fraction of 
β-galactosidase positive cells (Figure 8H). Furthermore, 
immunohistochemical analysis showed a highly increased 
expression of P16-INK4A, a key regulator of cellular 
senescence, in EC-8042-treated tumors (Supplementary 
Figure S7). Taken together, these results indicate that the 
in vivo sarcoma growth inhibition induced by EC-8042 is 
due to the induction of a senescent-state, while the anti-
tumor effects of doxorubicin are mainly caused by the 
promotion of apoptotic cell death.
DISCUSSION
In this work, we aimed to find new targeted 
therapies against soft tissue sarcomas using a model of 
sarcomagenesis in which, UPS or MLS arise from the 
cell-of-origin targeted with oncogenic mutations relevant 
for sarcoma development [3, 25, 36]. In search for 
altered transcription factor-mediated signaling, we found 
that SP1 is the most significantly altered transcription 
regulator in this model. Notably, a pro-tumorigenic role 
for SP TFs has been reported in several types of soft 
tissue sarcomas. Thus, SP1, SP3 and SP4 have been 
found overexpressed in rhabdomyosarcoma cells and 
fibrosarcoma-forming transformed human fibroblasts, 
and its downregulation using tolfenamic acid, reactive 
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Figure 7: EC-8042 inhibits the growth of MLS sarcoma xenografts derived from transformed hMSCs. Mice with 
established T-5H-FC#1 tumor xenografts were randomly assigned to 3 different groups (n=10, 6 and 5 in control, EC-8042 and doxorubicin 
groups respectively) and treated i.v. with saline buffer (control), EC-8042 at a dose of 18mg/Kg every 3 days (7 doses) or doxorubicin at a 
dose of 6 mg/Kg every 7 days (3 doses). A. Curves representing the mean tumor volume of T-5H-FC#1 xenografts during the treatments. 
Drug efficacy expressed as the percentage of tumor growth inhibition (%TGI) on day 15 is indicated. B. In vivo bioluminescence of 
tumors generated from luciferase-expressing T5H-FC#1 cells in a 3 mice-cohort of the indicated series at day 8 after the beginning of the 
indicated treatments. Average radiance values ± standard deviation are presented. C. Kaplan-Meier curves generated using the reaching of 
a tumor volume of 1000 mm3 as end-point event. D. Representative images (upper panel) and tumor weight (bottom panel) at the end of the 
experiment. E. Mean body weight of mice during the treatments. Doxorubicin was toxic and caused weight loss during the treatment. F–G. 
For the evaluation of CSC subpopulations after drug treatments we harvested xenograft tumors (n=3 per group) after a single dose treatment 
of EC-8042 (50mg/Kg) or doxorubicin (8 mg/kg) and dissociated them into single cells to evaluate the number of tumorspheres formed 
(F) and the tumor re-initiation ability in limiting dilution assays (G). The number of mice that grew tumors at week 3 and total number of 
inoculated mice for each condition is indicated (G). TIF was calculated using ELDA software. H. Mean tumor weight for each group at the 
end of the experiment (week 5). Error bars represents the standard error of the mean (SEM) and asterisks indicate a statistically significant 
difference in tumor volumes between the EC-8042 or doxorubicin-treated and control groups (*:p<0.05, **:p<0.005, ***: p<0.0005; 
two-sided Student t test). The log-rank test p value was used to estimate significant differences between control and drug treated groups in 
Kaplan-Meier analysis. In limiting dilutions assays Pr (>chiSq) referring to the control tumors are indicated.
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oxygen species (ROS)-inducing anticancer agents or 
specific siRNAs/U1snRNAs resulted in inhibited tumor 
growth [6, 8, 37, 38]. To inhibit the activity of SP1 and 
other SP family members in sarcoma TICs we have used 
a newly developed mithralog which shows a potent anti-
tumor activity while being less toxic than MTM and other 
mithralogs [17]. EC-8042 induced strong anti-proliferative 
effects that can be reproduced by SP1 knockdown using 
RNA interference. This data suggest that the inhibition of 
this transcription factor is a relevant mechanism of action 
Figure 8: In vivo anti-tumor activity of EC-8042 is associated to the induction of a senescent-like state. Pathological 
analysis of T5H-FC#1-generated tumors treated i.v. with saline buffer (control), EC-8042 at a dose of 18mg/Kg every 3 days (7 doses) 
or doxorubicin at a dose of 6 mg/Kg every 7 days (3 doses). A. H&E staining and immuno-staining detection of C-MYC, C/EBPα and 
cleaved PARP (cPARP). Necrotic (N) and myxoid (M) areas, and mitotic cells (red arrows) are indicated. Scale bars= 100μm (H&E 10X); 
50μm (C-MYC, C/EBPα and c-PARP); and 20 μm (H&E 40X). B–G. Quantification of tumor-related features including mitosis [number 
of mitotic figures per 10 high power fields (40X)] (B), necrosis (C), tumor grade score according to FNCLCC system (D), C-MYC (E) and 
C/EBPα (F) nuclear expression [number of cell showing nuclear staining per 10 high power fields (40X)] and apoptotic cells [number of 
cell showing nuclear staining for c-PARP and displaying apoptotic morphology per 10 high power fields (40X)] (G) in tumors from the 
indicated series. H. Analysis of senescent-associated β-galactosidase activity in ex vivo-established cell lines derived from tumors of the 
indicated series (n=4). Representative images (left panels; scale bars= 20 μm) and the quantification of the percentage of β-galactosidase + 
cells in 10 randomly selected fields (>600 total cells) of each cell line (right panel) are presented. Error bars represents the SEM and asterisks 
indicate a statistically significant difference in tumor volumes between the EC-8042 or doxorubicin-treated and control groups (*:p<0.05, 
**:p<0.005; two-sided Student t test).
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for EC-8042, as previously demonstrated for some ROS-
inducing drugs [38].
Importantly, we proved that this compound, EC-8042, 
is not recognized as a substrate by transporters of the ABC 
family. Several studies reported that SP1 and SP3 regulated 
the expression of ABC family member genes in different 
types of cancer cells, and that inhibition of SP1 activity 
with MTM downregulated the expression of ABC family 
genes and CSC-associated genes, inhibited proliferation 
and tumorigenicity, suppressed CSC-associated properties 
and caused chemosensitization to anti-cancer drugs [28, 
29, 39-41]. Similarly, we show that SP1 inhibition using 
EC-8042 results in the downregulation of ABCG2, ABCB1 
and ABCC1. In addition, EC-8042, opposite to doxorubicin, 
repressed the expression of many genes involved in the 
development of the CSC phenotype.
The amplification of C-MYC , one of the oncogenic 
genes with enhanced expression in our model of 
sarcomagenesis, is a frequent event in many types 
of sarcoma, including MLS [42]. EC-8042 treatment 
downregulates the expression of this oncogene in our 
model, in line with that described in ovarian cancer 
cells [20]. C-MYC may be regulated independently of 
SP1 by several anti-cancer drugs [38]. We showed that 
siRNA-mediated knockdown of SP1 induced C-MYC 
downregulation, suggesting that EC-8042 effect on 
C-MYC expression is mediated by SP1. In addition, 
genes involved in NOTCH signaling display a striking 
differential regulation after EC-8042 and doxorubicin 
treatments. In a similar way, the expression of the 
Hedgehog signaling receptor PTCH1 is repressed by 
EC-8042 but stimulated by doxorubicin. Importantly, 
both NOCHT and Hedgehog signaling routes have been 
found activated in CSC subpopulations of UPS, and their 
inhibition reduced the proportion of cells displaying CSC 
properties and suppressed tumor self-renewal [43].
The anti-tumor effect of EC-8042 in this model of 
sarcomagenesis was associated to a stronger reduction 
of the mitotic index, the induction of adipogenic 
differentiation, the initiation of a senescent-like state and 
the ability to target CSCs. Notably, senescence bypass 
in MSCs have been suggested as plausible mechanism 
for sarcoma development and therefore, senescence 
induction therapy could represent an efficient strategy 
against sarcoma [44]. Altogether, these data suggest that 
EC-8042 could act as an anti-pluripotency therapy able to 
target both CSCs and non-CSCs populations derived from 
sarcoma TICs.
MATERIALS AND METHODS
Cell types and drugs
Transformed hBMSCs cell lines were previously 
generated and characterized (Supplementary Figure S1A; 
[23-25]. The identity of transformed hBMSCs has been 
authenticated by Short Tandem Repeats analysis during 
the last 3 months. All the cell types were cultured as 
previously described [45]. Luciferase-expressing T-5H-
FC#1 cells were generated as described in Supplemental 
Information. Gene expression profiling of some of 
these cell types was previously reported and deposited 
(GSE48030; [25]). Analysis of upstream transcription 
regulator signaling significantly altered in transformed 
hBMSCs as compared to wt hBMSCs was performed 
with the list of differentially expressed genes (p value 
<0.05; regulation ≤2-fold) using Ingenuity Pathway 
Analysis (IPA) software 8.0 (Ingenuity Systems, Inc., 
Redwood City, CA). Stocks of EC-8042 and Doxorubicin 
(Sigma, St Louis, MO) were prepared as 1 mM solutions 
in sterile DMSO for in vitro experiments, maintained at 
-20 °C, and brought to the final concentration just before 
use. For in vivo experiments, EC-8042 and doxorubicin 
were prepared in sterile saline solution. All experimental 
protocols have been performed in accordance to approved 
institutional review board guidelines and were approved 
by the Institutional Ethics Committee of the Hospital 
Universitario Central de Asturias.
RT-qPCR assays
The expression of SP1, C-MYC, XIAP, ABCB1, 
ABCG2 and ABCC1 was assessed by qPCR as described 
in Supplemental Information. Primer sequences used are 
shown in Supplementary Table S1.
The Human Cancer Stem Cells RT2 Profiler PCR 
Array (PAHS-176-Z; SABiosciences, Qiagen Iberia, 
Madrid, Spain) was used to analyze the expression of 
84 genes linked to CSCs properties according to the 
manufacturer instructions (Supplemental Information; 
Supplementary Table S2). The analysis of altered signaling 
associated to genes affected by EC-8042 was performed 
using Ingenuity Pathway Analysis (IPA) software 8.0 
(Ingenuity Systems, Inc., Redwood City, CA).
Western blot
Whole cell protein extraction and western blot 
analysis were done as previously described [45]. 
Antibodies used are described in Supplemental 
Information.
siRNA transfection
SP1-especific siRNAs were from Sigma (siSP1#1; 
HU-01823-1) and from Dharmacon (Lafayette, CO) 
(siSP1#2; J-026959-05-0002). siGenome RiSC-
Free control siRNA (siControl; D-001220-01) were 
from Dharmacon. siRNA sequences are shown in 
Supplementary Table S1. Cells were transfected with 
100 pmol/ml siRNAs using Lipofectamine 3000 
(Life Technologies) according to the manufacturer’s 
instructions. 48 or 72 hours after transfection, cells were 
collected and analyzed [46].
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Transporter substrate and inhibition assays
The assessment of the ability of EC-8042 and 
MTM to inhibit ACBB1/MDR1 and ABCG2/BCRP1 or 
to be a substrate for these transporters were performed by 
Absorption Systems (Exton, PA) using MDR1- or BCRP-
expressing MDCK cells as described in Supplemental 
Information.
Cell viability assays
The viability of all cell lines in the presence 
and absence of drugs was determined using the Cell 
Proliferation reagent WST-1 (Roche, Mannheim, 
Germany) (Supplemental Information).
Tumorsphere culture
Cells lines or dissociated xenografts were plated at a 
density of 5,000 cells per well in 6-well plates treated with 
a sterile solution of poly 2-hydroxyethyl methacrylate (10 
g/l in 95% ethanol; Sigma) to prevent cell attachment, in 
serum-free sphere medium containing DMEM-F12 (GE 
Healthcare, Pittsburg, PA) supplemented with Glutamax 
(1:100; Life Technologies), B-27 Supplement (1:50; Life 
Technologies), Heparin (1:1000; Sigma), the growth 
factors human EGF (20 ng/ml) and human bFGF (10 ng/
ml; PeproTech, London, UK) and 1% methylcellulose 
(Sigma) to avoid cell aggregation. In addition, fresh 
aliquots of EGF and bFGF were added every three days. 
In xenograft-derived experiments, well-rounded spheres 
formed after 10 days of culture were counted. To analyze 
the effects of drugs in vitro, we treated adherent cultures 
with increasing concentrations of drugs for 72 h and 
then we grew them in tumorsphere culture conditions 
to assay the ability of the drugs to inhibit the formation 
of tumorespheres. Alternatively, 10-days spheres 
were incubated in sphere medium containing different 
concentrations of EC-8042 and doxorubicin for 4 days. 
After that, tumorspheres were scored, recovered by 
filtration through 70-μm cell strainers (Corning, New York, 
NY), washed with PBS and disaggregated by incubation 
with trypsin (0.25%)/EDTA (Life Technologies) for 
15 min. The resulting cell suspension was pelleted and 
resuspended in 1ml of normal growth medium containing 
10% FBS (Life Technologies). 150 μl of these cells 
suspensions were plated in triplicates in 96 well plates 
and incubated overnight to allow their attachment. Finally, 
cell viability was determined using the Cell Proliferation 
reagent WST-1 as above.
Immunofluorescence staining
Tumorspheres cultures were washed with 
phosphate-buffered saline (PBS) twice and fixed in 
4% paraformaldehyde (Sigma) in PBS for 20 minutes. 
Tumorspheres were then washed 3 times with PBS, 
permeabilized in PBS plus 0.1 % triton X-100 (Sigma) 
for 20 minutes, washed another 5 times with PBS and 
incubated with the blocking solution (10% goat serum in 
PBS) for 1 hour. After that, tumorspheres were incubated 
with anti-cleaved PARP [(ab32064), 1:500 dilution] from 
Abcam (Cambridge, UK) for 24 hours, washed 4 times 
with PBS plus 0.1% Tween-20 for 10 minutes, incubated 
with Alexa-555-conjugated anti-rabbit IgG [(A-21422), 
1:300 dilution] from Life Technologies for 1 hour, washed 
another 4 times with PBS plus 0.1% tween at 4 ºC and 
finally incubated with 300 ng/ml DAPI (Sigma) in PBS for 
24 hours at 4 ºC. The slides were washed extensively with 
PBS and pipetted into a drop of ProLong® Gold Antifade 
Mountant medium (P36930) from Life Technologies 
deposited in µ-Slide 8-well chambered coverslips (80826) 
from Ibidi (Planegg, Germany). Confocal sections images 
obtained with identical exposure times were collected 
using an Ultra-Spectral TCS-SP2-AOBS confocal 
microscope (Leica, Wetzlar, Germany).
Cell-cycle analysis
Cell-cycle analysis of floating and adherent cells 
was carried out as described previously [46].
Senescence-associated β-galactosidase staining
Cells were fixed and incubated overnight with X-gal 
solution (pH 6.0) as previously described [35].
Xenograft experiments
Female NOD/SCID mice of 5-6 weeks old 
(Janvier Labs, St Berthevin, France) were inoculated 
subcutaneously (s.c.) with 1x106 T5H-FC#1 cells. Once 
tumors reached 200-500 mm3, the mice were randomly 
assigned to receive intra-venous (i.v.) treatments of 
saline solution (control), EC-8042 at a dose of 18 mg/
kg every 3 days or doxorubicin at 6 mg/kg every 7 days. 
Animals were sacrificed by CO2 asphyxiation when the 
tumors reached approximately 2 cm. Mean tumor volume 
differences between groups were determined using a 
caliper or measuring the luminescence intensity using 
an IVIS Spectrum (Caliper Life Sciences, Hopkinton, 
MA) (Supplemental Information). The student t test 
was performed to determine the statistical significance 
between control and treated groups. Survival was 
represented using Kaplan-Meier analysis and the log-
rank test to estimate significant differences among groups 
(PAST 3.01 software). Drug efficacy was expressed 
as the percentage tumor growth inhibition (%TGI) 
(Supplemental Information). Upon tumor removal, 
a portion of some of the tumors was mechanically 
disaggregated to establish ex-vivo tumor cell lines as 
described [47]. In experiments aimed to analyze CSCs 
subpopulations after treatments, a single dose of EC-8042 
(50 mg/kg) or doxorubicin (8 mg/kg) were inoculated 48 
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hours before tumor extraction. Tumors were dissociated 
into single cell suspensions using MACS Tissue 
Dissociation Kit and the GentleMACS Dissociator 
system (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Mouse cells were removed from cell suspensions using 
Mouse Cell Depletion Kit (Miltenyi Biotec). For limiting 
dilution assays, serially diluted numbers of viable cells 
dissociated from xenografts were injected s.c. Tumor 
growth initiation was monitored for 5 weeks and tumor-
initiating frecuency (TIF) was calculated using the 
ELDA software [48]. Drug accumulation in tumors was 
analyzed as described in Supplemental Information. All 
animal research protocols were approved by the Animal 
Research Ethical Committee of the University of Oviedo 
prior to the study.
Histological analysis
Tumor samples were fixed in formol, embedded 
in paraffin, cut into 4-μm sections, and stained with 
hematoxylin and eosin (H&E). Tumor sections were 
also subjected to immunohistochemistry using the 
antibodies described in Supplemental Information [49]. 
Tumor grade was analyzed in H&E stained preparations 
using the French Federation of Comprehensive Cancer 
Centers (FNCLCC) grading system (Supplemental 
Information).
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